Wharton's jelly vs stem cells: what commercial products actually contain

The vocabulary problem: Wharton's jelly is not a cell type

Wharton's jelly is the name for a physical substance: the gelatinous connective tissue matrix that surrounds the blood vessels inside the umbilical cord. It is not the name of a cell, and a product labeled with that name describes where the material came from, not what cell content, if any, the finished product carries.

The overlap in marketing language comes from a real but narrower fact: early research into fresh, unprocessed umbilical cord tissue identified mesenchymal stromal cells residing within that matrix. Clinics searching for a stem cell supplier online may land on Wharton's jelly allograft listings because of that overlap in search terms, but a search-term connection is not evidence that a specific commercial, processed vial contains those cells in a viable, functional form.

What actually defines a stem cell, versus what a label claims

The International Society for Cell & Gene Therapy's minimal criteria define a multipotent mesenchymal stromal cell by three measurable properties: plastic adherence under standard culture conditions, a specific surface marker profile including CD73, CD90, and CD105 expression, and demonstrated tri-lineage differentiation capacity in culture. Each of those is a laboratory finding generated on live, cultured cells, not something a vial label or marketing page can establish on its own.

No mesenchymal stromal cell product currently carries FDA approval for orthopedic use. That is a separate fact from composition, but it belongs in the same conversation: regulatory status and cell content claims are both things a buyer should verify independently rather than infer from a product name.

What published analyses of commercial products have actually found

A 2026 analysis of six commercial Wharton's jelly products found low total cell counts and low viability overall, with only rare viable mesenchymal stromal cells identified across the products tested. A separate 2021 study of five commercial umbilical cord allograft products found no colony-forming mesenchymal stromal cells in any of them.

Taken together, the available published documentation for commercially processed cord-tissue allografts does not support calling these finished products stem cell products, even though the source tissue, in its fresh and unprocessed state, has been associated with that cell type in earlier research. The distinction between fresh-tissue research and finished-product testing is the one that matters for anyone evaluating a specific vial.

What finished-product testing shows, and what it doesn't explain

Commercial-product testing has reported low counts/viability and limited MSC findings. This does not establish why those findings occurred.

Evaluate finished-product documentation separately from native-tissue research; the approved summaries do not establish processing causation.

What to request before accepting a stem cell claim about any product

A specific claim deserves specific evidence, not a reference to the category as a whole.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.

• The lot certificate of analysis for the specific product and lot under consideration, not a category-level data sheet.
• Any viability or colony-forming data the supplier can produce for that product specifically, rather than a general reference to umbilical cord research.
• Clear language describing the product as a matrix or scaffold allograft if that is what the documentation supports, rather than marketing language describing it as a stem cell therapy.